Prostate-specific membrane antigen (PSMA) is of considerable interest as a target for diagnostics and therapy of prostate cancer patients. PSMA-targeted imaging has demonstrable value in guiding the management of the clinical evolution of prostatic cancer. The use of PSMA-targeted therapy using ¹⁷⁷Lu-labeled PSMA-617 is similarly effective and is progressing toward approval. The phase III VISION trial represents the largest well-designed and executed study of a theranostic pair. This article provides an overview of the phase III trial and delineates the different study arms and their implications in the assessment of efficacy. The VISION (phase III) trial will provide data of critical value to the field of theranostics and especially the field of prostatic cancer management.

前列腺特异性膜抗原 (PSMA) 作为前列腺癌患者诊断和治疗的靶标引起了相当大的兴趣。PSMA 靶向成像在指导前列腺癌临床演变管理方面具有明显的价值。使用¹⁷⁷ Lu 标记的 PSMA-617进行 PSMA 靶向治疗也同样有效，并且正在获得批准。III 期 VISION 试验代表了针对治疗诊断对的最大的精心设计和执行的研究。本文概述了 III 期试验，并描述了不同的研究组及其对疗效评估的影响。VISION（III期）试验将为治疗诊断学领域，尤其是前列腺癌管理领域提供具有关键价值的数据。